References

Myelofibrosis and survival prognostic models: a journey between past and future

10.3390/jcm12062188 · 2023 · External reference

Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story

10.1182/bloodadvances.2022007230 · 2022 · External reference

Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations

10.1038/s41375-019-0638-y · 2020 · External reference

Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival

10.1038/s41375-021-01183-8 · 2021 · External reference

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment

10.1038/s41375-023-02008-6 · 2023 · External reference

Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report

10.1182/blood-2010-11-320069 · 2011 · External reference

The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis

10.1002/cncr.30679 · 2017 · External reference

Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome

10.1182/bloodadvances.2022007128 · 2022 · External reference

Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera

10.1182/blood-2012-05-432989 · 2013 · External reference

Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib

10.1080/17474086.2017.1284583 · 2017 · External reference

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

10.3324/haematol.2019.235648 · 2020 · External reference

Final results of ruxopeg, a phase 1/2 adaptive randomized trial of ruxolitinib (Rux) and pegylated interferon alpha (IFNa) 2a in patients with myelofibrosis (MF)

10.1182/blood-2022-156389 · 2022 · External reference

The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms

10.1038/s41375-022-01613-1 · 2022 · External reference

MIPSS70+ version 2.0: mutation and karyotype-enhanced International Prognostic Scoring system for primary myelofibrosis

2018 · External reference

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

10.1182/blood-2013-03-488098 · 2013 · External reference